Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

Ex­tend­ed FTC re­view adds wrin­kle to Sanofi's $2.9B Proven­tion Bio buy­out

Sanofi is ex­tend­ing the dead­line for its $2.9 bil­lion ac­qui­si­tion of Proven­tion Bio to give an­titrust reg­u­la­tors more time to re­view the deal.

The French phar­ma gi­ant with­drew and re­filed the Pre­merg­er No­ti­fi­ca­tion and Re­port Form un­der the Hart-Scott-Rodi­no An­titrust Im­prove­ments Act “fol­low­ing in­for­mal dis­cus­sions with the staff of the” Fed­er­al Trade Com­mis­sion (FTC), it said in an SEC fil­ing. The agency, it added, need­ed more time to look at the deal and “in­for­ma­tion re­cent­ly pro­vid­ed to them.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.